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Extraskeletal problems and amyloid. The major clinical mani- CLINICAL FEATURES
festations of dialysis-associated Ab2M amyloidosis are chronic The prevalence of carpal tunnel syndrome, chronicarthralgias, destructive arthropathy and the carpal tunnel syn-
joint pain, and destructive arthropathy augments withdrome. For dialysis patients who have been maintained on
increasing time on dialysis and with aging [7]. After 15renal replacement therapy for more than 10–15 years, this
complication may become a major physical handicap. It may years of treatment, all patients have been shown to be
even be life-threatening in some instances due to cervical cord affected in some [8] but not all dialysis centers. Thus,
compression. Amyloid deposits in joint areas precede clinical prevalence appears to vary widely from one series to
symptoms and signs by several years. Systemic deposits may another and may be center-related, but differences mayalso occur but their clinical manifestations are infrequent. The
also be due to the use of different diagnostic criteria.diagnosis of dialysis arthropathy associated with b2-microglob-
Interestingly, based on a retrospective analysis, the prev-ulin-associated (Ab2M) amyloidosis mostly relies on indirect
clinical and radiological evidence. Histologic proof is rarely alence has recently been found to decrease in one center
obtained in vivo. The pathogenesis of the disease is complex. [9]. The factors involved in this apparent recent decrease
It includes reduced elimination of b2M and potentially also as in prevalence as compared to a previous time period,
impaired degradation of Ab2M as well as enhanced production have remained elusive.of Ab2M amyloid fibrils. Non enzymatic modifications of b2M
It is not yet definitely established whether there isprobably play a role, including b2M protein modification with
only one “dialysis-associated arthropathy” syndrome oradvanced glycation end-products (AGE) and advanced oxida-
tion protein products. Modified b2M, collagen and proteogly- whether there are several syndromes of distinct pathoge-
cans appear actively involved in the induction of a local in- netic origin. Therefore, a word of caution is needed con-
flammatory response and b2M amyloid formation. There is also cerning terminology. In the literature the terms of “dialysis-
evidence in favor of treatment-related factors such as the type
related amyloidosis,” “dialysis-associated arthropathy,”of hemodialysis membrane and the purity of dialysis water.
“dialysis-associated spondylarthropathy,” and “carpal tun-Hopefully, the translation of our improving knowledge of all
nel syndrome” are often used indistinguishably to desig-the factors involved will lead to a better treatment and eventu-
ally to the prevention of this dramatic complication of dialysis. nate the same syndrome in dialysis patients. However,
it is unclear whether these terms are interchangeable,
especially considering that to date there is no reliable,
The predominant features of b2-microglobulin-associ- noninvasive means at hand allowing diagnosis of incipi-
ent Ab2M amyloid deposits. Other types of arthropathyated amyloidosis (Ab2M) in end-stage renal disease pa-
may lead to similar or even identical manifestations intients are osteo-articular symptoms and signs and carpal
the absence of identifiable amyloid deposits. Moreover,tunnel syndrome. Clinical manifestations generally occur
it is also not yet clear whether in patients with Ab2Monly after many years of renal replacement therapy [1, 2].
amyloidosis the deposition of amyloid fibrils comes firstThe characteristic chronic arthralgias and arthropathies
and sets the stage for articular complications, or whethermay evolve to progressive joint destruction. Ab2M amy-
some unknown factor leads to subclinical joint lesions,loid deposits occur much earlier, however, than clinical
which are followed by the deposition of amyloid. Atsymptoms and signs, as has been recently shown in care-
present, it is probably wise to use the term of “dialysis-ful postmortem studies [3, 4]. They may occasionally be
related amyloidosis of the Ab2M type” for this syndromeobserved even in patients with long-standing, severe renal
in dialysis patients, after the exclusion of other, well-failure who are not yet treated by dialysis or related proce-
defined osteoarticular complications.dures [5, 6]. The deposits are mainly localized in osteo-
The chronic arthralgias are usually bilateral and oftenarticular structures, but systemic deposition may occur.
initially involve the shoulders. Other joints, in particular
the knees, wrists, and small joints of the hands, may be
involved as well. Chronic joint swelling is another impor-Key words: amyloidosis, b2-microglobulin, dialysis, joint involvement,
pathogenesis. tant feature of the disease, as may be recurrent hemar-
throsis and chronic tenosynovitis of the finger flexors. 1999 by the International Society of Nephrology
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Destructive arthropathies of large peripheral joints cysts and periarticular soft tissue swelling, in particular
thickening of the rotator cuff and biceps tendon [23].and of the spine may ensue, causing major incapacity.
Massive amyloid deposits are almost constantly observed The main radiological features of b2M amyloidosis
are subchondral bone cysts or articular erosions due toat the site of such lesions [10, 11]. They are observed
in hemodialysis patients and in continuous ambulatory replacement of subchondral bone by amyloid deposits.
Their frequency steadily increases with patient survival.peritoneal dialysis (CAPD) patients as well. Destructive
spondylarthropathy most frequently involves the cervical They may be found in 50–60% of patients treated for
more than 10 years [24, 25]. The prevalence of amyloidspine. It may be asymptomatic or lead to mild spinal
pain. In rare instances, however, it may cause nerve root cysts has been shown to be higher in patients treated
with standard cuprophane membrane than in patientscompression [12].
Carpal tunnel syndrome (CTS) is a prominent, rela- dialyzed with highly permeable and more biocompatible
membranes such as polyacrylonitrile AN-69 or polysul-tively early feature of Ab2M amyloidosis. An increasing
prevalence of shoulder pain and CTS with time on hemo- fone [7, 26, 27].
A CT scan may be useful to evaluate the size of bonedialysis treatment was initially reported by Charra et al.
[8]. It is of note that nearly all of their patients suffered defects with a high degree of precision. It also permits
assessment of the risk of fracture at various sites, includ-from CTS after 15 years of intermittent hemodialysis
treatment with cuprophane membrane and particularly ing the femoral neck, the knees, and the posterior verte-
bral arches of the spine.long dialysis sessions. This observation has been con-
firmed subsequently by others, although the incidence Bone scan using radiolabeled diphosphonate reveals
increased isotope uptake in areas of radiologically in-of CTS was often lower.
Systemic Ab2M amyloid deposits may occur in long- volved joints [28]. Such increased articular fixation is not
specific for dialysis amyloidosis, however, as it may beterm hemodialysis patients. Most often they are faint
and of no clinical importance [13], but in exceptional observed in synovitis of other origin as well. Scintigraphic
procedures using 123I-radiolabeled P component (SAP)cases they may cause serious complications such as bowel
infarction and perforation [14, 15] and cardiac failure [29] or 131I-radiolabeled b2M [30] are able to localize
amyloid deposits more specifically. However, the speci-[16]. The organs involved are the heart, the gastrointesti-
nal tract, and the lungs. Smaller deposits may also be ficity of the former is far from being perfect [17], and
the latter has been practically abandoned because of anseen in medium-sized blood vessels of virtually all vis-
ceral organs [13]. Surprisingly, only the spleen appears unacceptable radiation exposure. It has been replaced
more recently by 111In-radiolabeled b2M [31]. All theseto be generally devoid of b2M amyloid deposition [17].
The observation of systemic deposits raises the concern methods provide scintigraphic features that are at best
similar, though frequently less clear-cut, than those ob-that the development of Ab2M amyloidosis in dialysis
patients may be a threat not only to their well-being but tained by radiolabeled diphosphonates. Moreover, the
claimed site-specificity is questionable.occasionally also to their life, especially in cases of severe
cervical osteoarthropathy [18]. The possibility has also As to the differential diagnosis of cystic osteoarticular
lesions in dialysis patients, it may prove difficult to differ-to be considered that another type of amyloid fibril may
coexist in exceptional cases. This can occur either at the entiate brown tumors of secondary hyperparathyroidism
from amyloid cysts. Brown tumors are usually associatedsame location [19] or at different tissue sites, according
to the usual predilection site of each form of amyloido- with other features of severe osteitis fibrosa and may
expand to the bone cortex, in contrast to amyloid cysts.sis [20].
The incidence and clinical importance of systemic ex- Their distribution is frequently different, since brown
tumors usually affect the metaphysis or diaphysis of tu-tension of this type of amyloidosis still awaits more pre-
cise definition. bular bones, the jaws, ribs and iliac wings, whereas the
distribution of amyloid cysts is restricted to the vicinity
of synovial joints. Although brown tumors may also af-DIAGNOSIS
fect the epiphyseal bone in the vicinity of synovial joints,
Whereas clinical symptoms and signs grossly underes- subchondral bone cysts in long-term dialysis patients are
timate the degree of Ab2M amyloidosis, the histologic far more frequently due to amyloid cysts.
demonstration of Ab2M amyloid deposits remains the
diagnostic gold standard. The area most frequently in-
PATHOPHYSIOLOGYvolved is the sternoclavicular joint, as previously sug-
gested by us [21] and recently confirmed by others [22]. At present, the pathogenesis of Ab2M amyloidosis is
still incompletely understood. Theoretically, amyloido-In clinical practice, noninvasive diagnostic procedures
obviously are preferred to a biopsy. genesis can result from enhanced production of Ab2M
amyloid fibrils, diminished elimination of b2M, reducedUltrasonography may be helpful in detecting popliteal
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degradation of Ab2M, or a combination of these factors. Thus enzymatic and non-enzymatic modifications of
b2M may play a role, including b2M truncation by limitedExtremely high plasma b2M levels may be reached in
the anuric state reflecting primarily retention due to de- proteolysis [42] and b2M protein modification with ad-
vanced glycation end-products (AGE), leading to focalcreased renal elimination. It is possible that the accumu-
lation in plasma of b2M homologs such as granulocyte monocyte attraction and activation [43, 44]. The AGE-
transformed protein has been found to be modified withinhibitory proteins GIP I and GIP II, which cross-react
with commercially available assays for intact b2M [32, pentosidine [45], with Ne-(carboxymethyl)lysine [46] and
with other compounds. Another type of b2M modifica-33], accounts at least in part for the excessive plasma
values in anuric subjects. tion is the formation of advanced oxidation protein prod-
ucts (AOPP). They are markedly increased in uremia,Whether the daily b2M production rate is increased
or not in stable dialysis patients is still uncertain. Based in close association with plasma AGE-pentosidine and
dityrosine levels [47, 48]. The occurrence of enhancedon radioisotope dilution methods, it has been estimated
to be comparable to that of healthy subjects [34, 35]. oxidative stress during the hemodialysis session was re-
ported by the Necker group many years ago [49], andMethodological limitations would not allow one to detect
small differences in vivo, however. In addition, the pro- exposure of b2M to hydroxyl radicals has been shown
to lead to aggregation and dityrosine formation [50].duction rate probably differs from patient to patient, so
that studies with limited sample size lack statistical Oxidant-induced protein damage in dialysis patients, as
reflected by high plasma levels of AOPP [47, 48] orpower. Even in a given individual it may vary, for in-
stance in association with inflammatory events. These carbonyl [51], could be an important component in ure-
mia-related inflammatory processes, including the dial-factors could explain discrepant results between studies
done in vivo and in vitro. Some of the latter were sugges- ysis-associated arthropathy of the Ab2M type.
A question of major pathophysiologic interest istive of an increase in b2M production by mononuclear
cells in contact with the cuprophan membrane, but not whether b2M amyloid is an innocent bystander or an
active player. Several experimental and clinical findingsafter exposure to more biocompatible membrane [36, 37].
The amount of b2M which is produced day by day must are in favor of an active role. Thus native b2M, and even
more so AGE-b2M, are capable of directly enhancingbe eliminated through extrarenal, still unknown path-
ways. It is possible that most of the accumulated protein bone resorption via the induction of IL-1, IL-6 and tumor
necrosis factor (TNF) [52, 53]. The growth factor-likeis deposited as amyloid fibrils in osteoarticular structures.
An alternative possibility is that in advanced chronic activity ascribed to b2M could also be mediated by insu-
lin-like growth factor-1 and its receptor [54]. However,renal failure the relative contribution of extrarenal cata-
bolic pathways to the overall elimination of the protein the claimed active role of b2M as a bone cell mitogen
has been questioned by another group of authors [55].could be increased, whereas normally it is insignificant.
The influence of the hemodialysis procedure on the A preferential collagen binding affinity of b2M has been
reported which was dependent on the concentration ofkinetics of circulating b2M levels under various condi-
tions has been examined in many studies. The physical b2M and also on the amount of collagen present in the
in vitro preparation [56], and AGE-modified b2M hadcharacteristics of the dialysis membrane, namely its
structure, surface area, permeability and biocompatibil- an increased affinity for collagen, as had AGE-modified
collagen fo native b2M [57]. The latter findings probablyity, play an important role in the change of plasma b2M
during the dialysis session. Thus one can obtain either explain, at least in part, the predilection of b2M amyloid
for collagen-rich tissues such as joints. Another effect ofno or a more or less marked removal via diffusion, con-
vection, and/or adsorption. The use of standard cupro- b2M with potential relevance for the pathogenesis of
dialysis arthropathy is its capacity of inducing the synthe-phane and cellulose acetate membranes does not allow
one to remove significant amounts of b2M whereas the sis of fibroblast collagenase, similarly to the effect of
serum amyloid A, and thereby modifying the rate ofuse of highly permeable membranes, such as the polysul-
fone F-60 or the polyacrylonitrile AN-69 membrane, collagen breakdown [58].
In a retrospective clinical study we found an associa-allows to clear more or less marked amounts of the
polypeptide [38, 39] and to decrease the predialysis tion of high serum b2M levels with increased osteoclast
and osteoblast cell number with several serum markersplasma b2M level consistently [40, 41]. It remains to be
seen, however, whether the absolute plasma level of b2M of bone formation and resorption in chronic hemodialy-
sis patients [59]. We have recently been able to confirmand its kinetics are of great importance for the amyloido-
genic process. Probably inflammatory reactions pro- this finding in a prospective randomized study (unpub-
lished results). A similar association between plasma b2Mvoked by the contact with the dialysis membrane or
the extracorporeal treatment procedure in general and and indices of bone resorption has been observed in
osteoporotic postmenopausal women without renal fail-uremia-related or dialysis-related modifications of the
b2M molecule are of greater importance. ure [60]. These observations suggest that b2M is either
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